Abstract: The present invention provides the following method as an approach for enriching desired cells, particularly, yolk sac mesoderm cells or amniotic ectoderm cells, contained in an embryogenesis region-specific micropattern structure of a cell cluster formed by differentiation-inducing factors from a colony of pluripotent stem cells such as iPS cells: a method for producing a cell cluster enriched in desired cells from pluripotent stem cells, comprising the step of two-dimensionally culturing the pluripotent stem cells under Wnt signal regulation.

Abstract: The present invention provides a combination and method for treating a Temozolomide (TMZ)-resistant cancer patient, which comprises a combination of TMZ and an isoform-selective HDAC8 inhibitor, such as BMX at an effective relative ratio to overcome TMZ resistance by enhancing TMZ-mediated cytotoxic effect by downregulating the ?-catenin/c-Myc/SOX2 signaling pathway and upregulating WT-p53 mediated MGMT inhibition.

Abstract: The present invention provides drug toxicity evaluation platforms (such as an evaluation method and a kit therefor) that enable detailed analysis of the possibility and the like of developing drug-induced damage (such as DILI) to the liver and other organs. The method for evaluating drug toxicity of the present invention includes: a step of adding a drug to a co-culture system of an organoid and blood cells; and a step of evaluating the toxicity of the drug to the organoid.

Abstract: A method is presented for treating viral and fungal infections by applying a topical immunosensitizer to the skin of a person infected with a virus or fungus and in need of treatment for the viral or fungal infection. Methods of improving anti-viral and anti-fungal immunity are also presented, and methods of increasing PBMC interferon gamma expression in response to a viral or fungal immune stimulus.

Abstract: In an embodiment, an object of the present invention is to provide a double-stranded nucleic acid complex having a novel structure. In an embodiment, the present invention relates to a nucleic acid complex comprising a first nucleic acid strand and a second nucleic acid strand, wherein said first nucleic acid strand: (1) is capable of hybridizing to at least a part of a target transcriptional product; (2) has an antisense effect on the target transcriptional product; and (3) is a gapmer comprising a central region, and a 5? wing region and a 3? wing region, said second nucleic acid strand comprises at least one sugar-unmodified central region (first exposed region) consisting of one sugar-unmodified ribonucleoside or two or three contiguous sugar-unmodified ribonucleosides linked by an internucleoside bond, which is or are complementary to a part of said first nucleic acid strand, and said first nucleic acid strand is annealed to said second nucleic acid strand.

Abstract: Provided is a composition for promotion of the regeneration of the nucleus pulposus of an intervertebral disc, said composition comprising a low endotoxin monovalent metal salt of alginic acid and mesenchymal stem cells. In particular, the composition of the present invention promotes the regeneration of the nucleus pulposus of an intervertebral disc via activation of nucleus pulposus cells by human bone marrow-derived high-purity mesenchymal stem cells and/or differentiation of human bone marrow-derived high-purity mesenchymal stem cells into nucleus pulposus cells.

Abstract: The present invention is a glutamine compound having a high Z element attached via a ligand, which enters the mitochondrion and is subsequently exposed to ionizing radiation. When exposed to ionizing radiation, the present invention damages mitochondrial (as well as other) substructures such as mtDNA, the outer membrane, the inner membrane, cristae, ribosomes, etc., and causes the effective destruction of such mitochondrion. Tumorigenic cells without mitochondria cannot produce the energy they need to subsist and replicate, effectively starving them of energy and causing their destruction.

Abstract: The present invention relates to: a novel method for preparing a heterocyclic derivative compound of chemical formula I below; a novel intermediate compound used in the preparation method; a composition for treatment or prevention of hyperuricacidemia, gout, nephritis, chronic renal insufficiency, nephrolith, uremia, urolithiasis, or a uric acid-related disease, the composition containing the compound of chemical formula I at a dose of more than 2 mg and equal to or less than 10 mg and being orally administered once a day; and a hydrochloride 1.5 hydrate of the novel compound of chemical formula I.

Abstract: Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5 c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available for Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described.

Abstract: The present invention relates to a method of treating drug addiction and reducing dependence or tolerance on a dependence-inducing opiate drug, wherein the method comprises administering to a subject a compound having the structure of formula (I): having the IUPAC name of (?)3-((S)-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)(3-thienyl)methyl)phenol, or pharmaceutically acceptable esters or salts thereof, wherein the compound has activity on the mu, delta and kappa opioid receptors thereby providing added analgesia with an improved therapeutic index and reduced risk of respiratory depression.

Abstract: Described herein, inter alia, are compositions and methods for treating or preventing obesity and using the same.

Abstract: Formulations and methods for treating fibromyalgia or chronic pain in humans comprising chronically administering to a human patient experiencing fibromyalgia who is experiencing insulin resistance a pharmaceutical composition comprising a therapeutically effective amount of a drug that treats insulin resistance and a therapeutically effective amount of a drug for treating the pain associated with fibromyalgia. In certain preferred embodiments, the formulation is an oral solid dosage form.

Abstract: The present invention addresses the problem of providing a tablet that contains a high concentration of acetaminophen, satisfies an acetaminophen dissolution rate from the tablet of at least 80% in 15 minutes, and can be manufactured by dry direct compression. The present invention provides a tablet including: acetaminophen that has a median particle diameter in a range from 100 to 350 µm; crystalline cellulose that has a bulk density in a range from 0.10 to 0.23 g/cm3; and at least two types of disintegrants. The at least two types of disintegrants are (a) at least one disintegrant selected from the group consisting of crospovidone, croscarmellose sodium, and sodium starch glycolate, and (b) a disintegrant that is a low-substituted hydroxypropyl cellulose. The acetaminophen content per tablet is at least 86 weight%.

Abstract: Disclosed herein are compositions comprising GLP-1 and/or GLP-1 analog(s) for treating or preventing non-alcoholic steatohepatitis (NASH).

Abstract: An amorphous solid form of a compound comprising of the angiotensin receptor antagonist (ARB) valsartan, the neutral endopeptidase inhibitor (NEPi) (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methylpentanoic acid ethyl ester and sodium cations is provided. This is compound is useful for the treatment of hypertension and/or heart failure.

Abstract: The present invention provides a solid preparation comprising, based on 100 parts by weight of the solid preparation, a self-emulsifying composition comprising 0.1 to 0.5 parts by weight of dutasteride, 6 to 110 parts by weight of oil and 6 to 110 parts by weight of a surfactant, and 5 to 185 parts by weight of a coating excipient having pores accommodating the self-emulsifying composition formed in a surface thereof, and a method of manufacturing the solid preparation.

Abstract: Disclosed herein are combinational therapies for diabetes comprising a first effective amount of one or more first active ingredients selected from the group consisting of GLP-1 and GLP-1 analogs and a second effective amount of one or more second active ingredients selected from the group consisting of insulin and insulin analogs.

Abstract: Disclosed herein are dosing regimens of GLP-1 and/or GLP-1 analog(s).

Abstract: Described herein are syringe devices comprising a syringe including a therapeutic dose of at least one drug to be used in a drug or substance overdose.

Abstract: Described herein are pharmaceutical compositions including omeprazole and a benzimidazole drug. In some embodiments, the compositions can be formulated for oral administration. The compositions can be used to treat gastrointestinal conditions. Methods of treatment using the compositions are also described.